TLSI
TriSalus Life Sciences, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$5.00
+0.40%Year over year
Reported trailing growth
- Revenue
- +25.2%
- EBITDA
- +15.5%
- EBIT
- +1.5%
- EPS
- -9.2%
- Free cash flow
- -2.2%
- Operating cash flow
- -3.2%
Forward estimates
Based on analyst estimates
- Revenue
- +48.9%
- EBITDA
- +28.8%
- EPS
- +70.1%
Three-year CAGR
- Revenue
- +53.9%
- EBITDA
- -2.1%
- EBIT
- +25.5%
- Net income
- -18.0%
- EPS
- -47.2%
- Free cash flow
- +54.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026